


Best Pharmaceuticals for Children Act



OMB # 0925-0648

Expiration Date: 6/30/2024


Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0642). Do not return the completed form to this address.

Thank you for attending the 10th Annual Meeting of T32 Trainees! Please take a few minutes to evaluate this meeting. Our goal is to obtain feedback so that we can improve the next meeting.

Responses are anonymous. As such, we are unable to respond to feedback submitted here. If you would like a response to a comment or question, please email us at bpca@infinityconferences.com.


Please select the choice below that best describes your role at this meeting.

- Pediatric Clinical Pharmacology Fellow
- Other Pediatric Fellow
- Adult Clinical Pharmacology Fellow
- Other Adult Fellow
- Former Fellow
- PI/Program Director
- Other (FDA, NIH, etc.)



Best Pharmaceuticals for Children Act

NIH Eunice Kennedy Shriver National Institute
of Child Health and Human Development



Virtual Meeting Logistics

Were you satisfied with the frequency and quality of pre-meeting communications regarding virtual participation?

Yes

No

Additional Comments

On a scale of 1 to 5 with 5 being the best, how would you rate the quality of support received during the virtual meeting?

1 (poor)

5 (excellent)


N/A

★	★	★	★	★	○
---	---	---	---	---	---

Additional Comments

Best Pharmaceuticals for Children Act

NIH Eunice Kennedy Shriver National Institute
of Child Health and Human Development



Agenda Feedback

On a scale of 1 to 5, with 5 being the best, how would you rate the following session on August 16:

1:40-2:40 PM: There and Back Again - Atypical Career Paths (Barrett)

1 (poor)

5 (excellent)


N/A

★	★	★	★	★	○
---	---	---	---	---	---

Additional Comments

Best Pharmaceuticals for Children Act

NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development



Agenda Feedback

On a scale of 1 to 5, with 5 being the best, how would you rate the following sessions on August 17:

1:35-2:35 PM: Clinical Pharmacology and Regulatory Science at the FDA - Opportunities and Career Paths (Schuck)

1 (poor)

5 (excellent)

N/A

<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

Additional Comments

4:55-5:15 PM: Making Drugs Safer and More Effective for Kids: An Overview of the Pediatric Trials Network (Greenberg)

1 (poor)


5 (excellent)


N/A

<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

Additional Comments

Best Pharmaceuticals for Children Act

 Eunice Kennedy Shriver National Institute of Child Health and Human Development



Agenda Feedback

Which career development breakout session did you attend?

- Grant Writing/Specific Aims
- Mentor-Mentee Mojo
- Scientific Publishing
- I did not attend a breakout session

On a scale of 1 to 5, with 5 being the best, how would you rate this session.

1 (poor)					5 (excellent)	N/A
★	★	★	★	★	★	<input type="radio"/>


Additional Comments

On a scale of 1 to 5, with 5 being the best, how would you rate the usefulness of the quiz with board-related questions?

1 (poor)					5 (excellent)	N/A
★	★	★	★	★	★	<input type="radio"/>


Additional Comments

Please provide your feedback on the fellow presentations.



Best Pharmaceuticals for Children Act

NIH Eunice Kennedy Shriver National Institute
of Child Health and Human Development



General Feedback

On a scale of 1 to 5, with 5 being the best, what is your overall rating of the Tenth Annual Meeting of T32 Trainees?

1 (poor)

5 (excellent)

★	★	★	★	★
---	---	---	---	---

What is the main reason for your rating?

Please provide any additional comments regarding the virtual meeting format, agenda content, or logistical support. Include any suggestions for next year's meeting.